Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Compass Pathways Plc's Business Segments
Compass Pathways Plc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Single Operating
Total Revenue
-
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Single Operating0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Operating | - | - |
Annual Results
Revenue Share by Reportable Segment - FY
- Single Operating0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Single Operating | - | - |
Description of Compass Pathways Plc
Compass Pathways Plc is a UK-based pharmaceutical company focused on the development of innovative therapies for mental health patients. The company was founded in 2016 and is headquartered in London, UK. Compass Pathways is a leader in the field of psychedelic-assisted therapy, a promising new approach to the treatment of depression and other mental health disorders using psychedelic compounds.
The company's flagship product is a synthetic form of psilocybin, the psychoactive compound found in magic mushrooms. Compass Pathways has completed a phase 2 clinical trial of this product in patients with treatment-resistant depression, and is currently planning to initiate a phase 3 trial. The company is also pursuing other drug development programs, including a proprietary formulation of ketamine.
Compass Pathways has a highly experienced management team, led by co-founder and CEO George Goldsmith. The company has a strong financial position, with over $150 million in funding from investors, including the venture arms of tech giants like Peter Thiel, Bill Gates, and Jeff Bezos. In 2020, the company went public on the Nasdaq stock exchange with a valuation of over $1 billion.
Compass Pathways is committed to scientific rigor and safety in the development of psychedelic-assisted therapies. The company has formed partnerships with leading academic institutions and research organizations to conduct trials and gather data on the safety and efficacy of these therapies. Compass Pathways is also focused on building a sustainable business model that ensures broad access to these therapies for patients in need.
Overall, Compass Pathways is a pioneering company in the emerging field of psychedelic-assisted therapy, with a bold vision for improving mental health outcomes through innovative drug development and clinical research.
The company's flagship product is a synthetic form of psilocybin, the psychoactive compound found in magic mushrooms. Compass Pathways has completed a phase 2 clinical trial of this product in patients with treatment-resistant depression, and is currently planning to initiate a phase 3 trial. The company is also pursuing other drug development programs, including a proprietary formulation of ketamine.
Compass Pathways has a highly experienced management team, led by co-founder and CEO George Goldsmith. The company has a strong financial position, with over $150 million in funding from investors, including the venture arms of tech giants like Peter Thiel, Bill Gates, and Jeff Bezos. In 2020, the company went public on the Nasdaq stock exchange with a valuation of over $1 billion.
Compass Pathways is committed to scientific rigor and safety in the development of psychedelic-assisted therapies. The company has formed partnerships with leading academic institutions and research organizations to conduct trials and gather data on the safety and efficacy of these therapies. Compass Pathways is also focused on building a sustainable business model that ensures broad access to these therapies for patients in need.
Overall, Compass Pathways is a pioneering company in the emerging field of psychedelic-assisted therapy, with a bold vision for improving mental health outcomes through innovative drug development and clinical research.
Compass Pathways Plc is a clinical-stage mental health care company dedicated to developing and commercializing innovative therapies, particularly focusing on addressing treatment-resistant depression (TRD). The company’s strategic approach encompasses various segments, products, and services designed to enhance the mental health landscape for those affected by this challenging condition.
Segments
Compass Pathways operates primarily within a single segment that concentrates on developing novel therapies for mental health disorders. This focused segment enables the company to allocate resources effectively, leveraging advancements in psychedelic research, particularly around psilocybin, to meet the urgent needs of patients suffering from TRD. The emphasis on a singular segment reflects a commitment to specialization, allowing the company to drive forward and innovate within this complex therapeutic area.
Products
1. COMP360
COMP360 is the cornerstone product of Compass Pathways and represents a significant advancement in the treatment of TRD. This proprietary formulation consists of synthetic psilocybin, a compound derived from psychedelic mushrooms that has shown promise in altering cognitive and emotional processes involved in depression. The development of COMP360 is marked by several key achievements:
- Breakthrough Therapy Designation: The product has been granted Breakthrough Therapy status by the US Food and Drug Administration (FDA), which signifies its potential to offer significant therapeutic advancements over existing treatment options. This designation accelerates the development and review processes, underscoring the urgency and promise associated with COMP360.
- Clinical Trials: Compass Pathways has engaged in a series of clinical trials to assess the efficacy and safety of COMP360. These studies focus on various dosages, treatment regimens, and the integration of psychotherapy, aiming to yield robust data that supports regulatory approval and ultimately enhances its therapeutic profile.
COMPASS Pathways Program
In addition to the specific product, Compass Pathways has established the COMPASS Pathways Program, which represents a comprehensive treatment approach integrating psilocybin-based therapies with psychotherapy. This program embodies key principles:
- Holistic Treatment: The program is designed to provide a holistic perspective, recognizing that effective treatment of TRD cannot solely rely on pharmacological agents. The combination of psychotherapy with psilocybin reinforces the company’s commitment to addressing the mental and emotional needs of patients comprehensively.
- Patient-Centric Approach: The treatment model emphasizes personalized care, ensuring that therapies are tailored to meet the individual needs and circumstances of patients, which is critical in the management of complex mental health disorders.
Services
Compass Pathways also provides a suite of services that supports not only the development and commercialization of its products but also enriches the overall care ecosystem for patients suffering from TRD. Key service offerings include:
1. Clinical Research
Compass Pathways invests heavily in clinical research to comprehensively evaluate the safety and efficacy of its therapies. This research involves:
- Partnerships with Academic Institutions: The company collaborates with prominent academic institutions worldwide, combining expertise and resources to conduct high-quality clinical trials. These partnerships enhance the validity of research outcomes and foster innovation in therapeutic approaches.
- Multifaceted Trial Designs: Clinical studies employ diverse methodologies to assess various aspects of treatment, including dosage optimization, patient selection criteria, and synergy with psychotherapeutic interventions. Such rigor is essential for establishing a clear evidence base for future therapies.
Regulatory Affairs
Navigating the regulatory landscape is crucial for Compass Pathways, and the company provides services in regulatory affairs, including:
- Compliance Management: Ensuring that all developmental stages of its products meet regulatory requirements, thus facilitating smoother approval processes with agencies like the FDA and EMA (European Medicines Agency).
- Guidance Through Regulatory Processes: Compass Pathways offers consultation and support to help guide its research and clinical programs through complex regulatory frameworks, maintaining transparency and compliance at all stages.
Commercialization
With a robust strategy for commercialization, Compass Pathways focuses on the successful market entry of its products by providing:
- Marketing and Sales Support: Building awareness and understanding of its products among healthcare professionals and patients, Compass Pathways utilizes targeted marketing strategies. This includes educational programs, outreach efforts, and partnerships with healthcare providers.
- Distribution Networks: The company develops strategic distribution networks to ensure its therapies are accessible and efficiently delivered to healthcare settings where they are needed most.
Patient Access
Recognizing the importance of accessibility to effective treatment, Compass Pathways is dedicated to providing services that facilitate patient access to its therapies:
- Patient Support Programs: The company offers resources to assist patients in navigating the healthcare system, including information about treatment options, insurance coverage, and reimbursement processes.
- Advocacy for Accessibility: Compass Pathways actively engages in initiatives that promote the accessibility of mental health treatments, advocating for policies that support equitable healthcare access for all individuals managing TRD.
In summary, Compass Pathways Plc is making significant strides in the mental health arena, particularly in the realm of treatment-resistant depression. Through its innovative products, comprehensive treatment programs, and a suite of supportive services, the company aims to transform the way mental health disorders are treated, ultimately enhancing the quality of life for countless individuals affected by these challenging conditions.
Segments
Compass Pathways operates primarily within a single segment that concentrates on developing novel therapies for mental health disorders. This focused segment enables the company to allocate resources effectively, leveraging advancements in psychedelic research, particularly around psilocybin, to meet the urgent needs of patients suffering from TRD. The emphasis on a singular segment reflects a commitment to specialization, allowing the company to drive forward and innovate within this complex therapeutic area.
Products
1. COMP360
COMP360 is the cornerstone product of Compass Pathways and represents a significant advancement in the treatment of TRD. This proprietary formulation consists of synthetic psilocybin, a compound derived from psychedelic mushrooms that has shown promise in altering cognitive and emotional processes involved in depression. The development of COMP360 is marked by several key achievements:
- Breakthrough Therapy Designation: The product has been granted Breakthrough Therapy status by the US Food and Drug Administration (FDA), which signifies its potential to offer significant therapeutic advancements over existing treatment options. This designation accelerates the development and review processes, underscoring the urgency and promise associated with COMP360.
- Clinical Trials: Compass Pathways has engaged in a series of clinical trials to assess the efficacy and safety of COMP360. These studies focus on various dosages, treatment regimens, and the integration of psychotherapy, aiming to yield robust data that supports regulatory approval and ultimately enhances its therapeutic profile.
COMPASS Pathways Program
In addition to the specific product, Compass Pathways has established the COMPASS Pathways Program, which represents a comprehensive treatment approach integrating psilocybin-based therapies with psychotherapy. This program embodies key principles:
- Holistic Treatment: The program is designed to provide a holistic perspective, recognizing that effective treatment of TRD cannot solely rely on pharmacological agents. The combination of psychotherapy with psilocybin reinforces the company’s commitment to addressing the mental and emotional needs of patients comprehensively.
- Patient-Centric Approach: The treatment model emphasizes personalized care, ensuring that therapies are tailored to meet the individual needs and circumstances of patients, which is critical in the management of complex mental health disorders.
Services
Compass Pathways also provides a suite of services that supports not only the development and commercialization of its products but also enriches the overall care ecosystem for patients suffering from TRD. Key service offerings include:
1. Clinical Research
Compass Pathways invests heavily in clinical research to comprehensively evaluate the safety and efficacy of its therapies. This research involves:
- Partnerships with Academic Institutions: The company collaborates with prominent academic institutions worldwide, combining expertise and resources to conduct high-quality clinical trials. These partnerships enhance the validity of research outcomes and foster innovation in therapeutic approaches.
- Multifaceted Trial Designs: Clinical studies employ diverse methodologies to assess various aspects of treatment, including dosage optimization, patient selection criteria, and synergy with psychotherapeutic interventions. Such rigor is essential for establishing a clear evidence base for future therapies.
Regulatory Affairs
Navigating the regulatory landscape is crucial for Compass Pathways, and the company provides services in regulatory affairs, including:
- Compliance Management: Ensuring that all developmental stages of its products meet regulatory requirements, thus facilitating smoother approval processes with agencies like the FDA and EMA (European Medicines Agency).
- Guidance Through Regulatory Processes: Compass Pathways offers consultation and support to help guide its research and clinical programs through complex regulatory frameworks, maintaining transparency and compliance at all stages.
Commercialization
With a robust strategy for commercialization, Compass Pathways focuses on the successful market entry of its products by providing:
- Marketing and Sales Support: Building awareness and understanding of its products among healthcare professionals and patients, Compass Pathways utilizes targeted marketing strategies. This includes educational programs, outreach efforts, and partnerships with healthcare providers.
- Distribution Networks: The company develops strategic distribution networks to ensure its therapies are accessible and efficiently delivered to healthcare settings where they are needed most.
Patient Access
Recognizing the importance of accessibility to effective treatment, Compass Pathways is dedicated to providing services that facilitate patient access to its therapies:
- Patient Support Programs: The company offers resources to assist patients in navigating the healthcare system, including information about treatment options, insurance coverage, and reimbursement processes.
- Advocacy for Accessibility: Compass Pathways actively engages in initiatives that promote the accessibility of mental health treatments, advocating for policies that support equitable healthcare access for all individuals managing TRD.
In summary, Compass Pathways Plc is making significant strides in the mental health arena, particularly in the realm of treatment-resistant depression. Through its innovative products, comprehensive treatment programs, and a suite of supportive services, the company aims to transform the way mental health disorders are treated, ultimately enhancing the quality of life for countless individuals affected by these challenging conditions.